Document is current
Any future updates will be listed below
-
Authors
Kret, Zaina S.
Sweder, Ryan J.
Pollock, Raphael
Tinoco, Gabriel https://orcid.org/0000-0002-2565-6124
- License Information
-
More Information
Article History
Accepted: 13 April 2025
First Online: 27 April 2025
Declarations
:
: No external funding was used in the preparation of this article.
: Gabriel Tinoco has served on the advisory boards for vimseltinib with Deciphera in 2025 and 2024, pexidartinib with Daiichi Sankyo in 2024, and ivosideninib with Servier Pharmaceuticals in 2023, none of which was relevant to the content of this article. Zaina S. Kret, Ryan J. Sweder, and Raphael Pollock have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: No datasets were generated or analyzed during the current study.
: Not applicable.
: Conceptualization: GT, RP. Data curation: GT. Formal analysis: GT. Funding acquisition: N/A. Investigation: GT, ZK, RS, RP. Methodology: GT. Project administration: GT. Software: GT. Resources: GT. Supervision: GT, RP. Validation: GT, RP. Visualization: ZK. Writing (original draft): GT, ZK, RS, RP. Writing (review and editing): GT, ZK, RS, RP.
